Establishing the phenotype in novel acute and chronic murine models of allergic asthma
Introduction
Ascertaining whether asthma is present in humans is usually based on the presence of clinical symptoms such as episodic cough, wheezing, breathlessness and chest tightness and on a characteristic history and variability in lung function measured with spirometry or peak-flow measurements [1]. However, a diagnosis based largely on consistent symptoms and home peak-flow reading is often inaccurate due to poor patient technique and compliance, requiring further investigation [2]. In vivo animal models of the disease help to understand the pathogenesis of asthma permitting the study of parameters that would be difficult to assess in humans and have ethical problems. An ideal animal model should resemble the major features of human asthma. Asthma is a chronic disease of the airways characterised by the chronic presence of inflammatory cells such as eosinophils, mast cells and T lymphocytes, with superimposed acute inflammatory episodes which correspond to exacerbations of asthma [3], [4], [5]. In addition, asthmatic airways undergo chronic airway remodelling that, together with the accumulation of inflammatory cells, may contribute to the development of airway hyperresponsiveness (AHR). This consists of an exaggerated response of the airways to a variety of non-specific stimuli contributing to exacerbations of asthma [6], [7].
Allergic asthma is the most prevalent type of asthma affecting two thirds of the total asthmatic population and 80% of asthmatic children and adolescents [8], [9]. The acute asthmatic response after antigen inhalation in sensitised atopic asthmatic patients results in an early asthmatic response (EAR) which develops immediately after challenge reaching a maximal bronchoconstriction between 15 and 30 min and generally resolving within 1---3 h [10], [11]. The EAR is the result of an immediate IgE-dependent type I hypersensitivity reaction driven by the activation of mast cells, alveolar macrophages, dendritic cells and airway epithelial cells among others [12]. These cells release mediators such as histamine, prostaglandins, leukotrienes and thromboxanes that are involved in the bronchoconstriction, mucus secretion and microvascular leakage observed during the EAR. In addition, these mediators release cytokines and chemotactic factors that are essential for the recruitment and activation of further inflammatory cells involved in the development of the late asthmatic response (LAR) in some patients [10], [12]. Depending on the intensity and duration of the stimuli, approximately 60% of asthmatic patients are dual responders eliciting two temporally distinct bronchoconstrictor responses [13], [14]. This LAR is characterised by a slowly progressive and persistent bronchoconstriction that begins 3---4 h after allergen provocation, peaks between 6 and 12 h and generally resolves within 24 h [13]. The late phase response develops as a result of activation of inflammatory cells which release pro-inflammatory mediators contributing to the development of allergen-induced AHR [11] and perpetuating the asthmatic inflammatory response [12] typical of chronic human asthma.
Animal models have been developed to study the pathogenesis of asthma. Guinea-pig models of asthma can provide the essential hallmarks of asthma, including dual bronchoconstrictor responses (EAR and LAR) [15], [16], [17], [18]. However, asthma models in mice are potentially more useful due to the fact that their immune system has been extensively characterised, genetically modified animals (knockout, transgenic and immunodeficient mice) are available and a wide range of species-specific reagents can be obtained [9], [19]. Different protocols have been employed for induction of allergic asthma in mice, and can be differentially classified into acute or chronic models depending on the number of exposures to the allergen. Acute models of allergic asthma expose the animals to the allergen over a relatively short period of time, obtaining an asthma-like phenotype that resembles human asthmatic airways during exacerbations of the disease. On the other hand, chronic models expose the animals to the allergen over longer periods to mimic the recurrent long-term exposure to low concentrations of allergen experienced by people with asthma [9]. In this report, we compare the effects of acute and chronic exposure to allergen on asthmatic hallmarks developed in two novel murine models of allergic asthma receiving the same sensitisation. While there have been a number of studies using acute and chronic exposures of mice to allergen, this study describes for the first time a chronic murine model of allergic asthma that displays both EAR and LAR, alongside measures of AHR, serum antibody levels and lung inflammatory cell counts.
Section snippets
Sensitisation and challenge
Male BALB/c mice weighing 20---25 g were maintained under conventional animal housing conditions receiving food and drinking water ad libitum. All studies complied with the guidelines for the care and use of laboratory animals according to the Animals (Scientific Procedures) Act 1986. All mice except the naïve animals were sensitised on days 0 and 5 by i.p. injection of ovalbumin (OVA, 100 µg/mouse) and aluminium hydroxide (10%, 50 mg/mouse) in phosphate-buffered saline (PBS). Twelve days after
Allergen-induced airways responses
The final inhalation challenge of OVA in acute and chronically OVA-exposed mice showed two temporally distinct bronchoconstrictor responses (Fig. 1A and B). Increases in Penh were observed immediately after OVA challenge, reaching a maximum 2 h later in both models. This phase was followed by a LAR with maximal Penh values at 7 h after OVA challenge in the acute model (Fig. 1A) and at 8 h in the chronic model (Fig. 1B). The Penh values at time points corresponding to the maximum EAR and LAR in
Allergen-induced airways responses, cellular infiltration and levels of total IgE and OVA-specific IgG
Novel models of allergic asthma have been developed in male mice with the aim of reproducing the major features of the human condition in order to address both the acute and chronic condition of the airways during asthma. The asthmatic response after antigen inhalation in patients with allergic asthma results in an EAR due to an IgE-dependent type I hypersensitivity reaction [12]. This asthmatic feature was reproduced in both acute and chronic murine models of allergic asthma which showed an
Acknowledgements
We are grateful to Buxco Research Systems (U.K.) for the loan of the whole-body plethysmography equipment.
References (51)
- et al.
Asthma
Lancet
(2002) - et al.
Animal models of type I allergy using recombinant allergens
Methods
(2004) - et al.
Selective airway responsiveness in asthma
Trends Pharmacol Sci
(1999) - et al.
Use of the mouse to unravel allergic asthma: a review of the pathogenesis of allergic asthma in mouse models and its similarity to the condition in humans
Arch Bronconeumol
(2005) - et al.
Early and late asthmatic reaction after allergen challenge
Respir Med
(1994) - et al.
Different profiles of T-cell IFN-gamma and IL-12 in allergen-induced early and dual responders with asthma
J Allergy Clin Immunol
(2005) - et al.
Inflammatory cells in asthma: mechanisms and implications for therapy
J Allergy Clin Immunol
(2003) - et al.
Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs
Eur J Pharmacol
(1995) - et al.
Bronchoconstriction and airway hyperresponsiveness after ovalbumin inhalation in sensitized mice
Eur J Pharmacol
(1995) - et al.
Optimization of the sensitization conditions for an ovalbumin challenge model of asthma
Int Immunopharmacol
(2007)
TNF-alpha induces the late-phase airway hyperresponsiveness and airway inflammation through cytosolic phospholipase A(2) activation
J Allergy Clin Immunol
New insights into the relationship between airway inflammation and asthma
Clin Sci (Lond)
Pathophysiology of asthma
Br J Clin Pharmacol
Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma
J Pharmacol Exp Ther
Characteristics of airway hyperresponsiveness in asthma and chronic obstructive pulmonary disease
Am J Respir Crit Care Med
An improved murine model of asthma: selective airway inflammation, epithelial lesions and increased methacholine responsiveness following chronic exposure to aerosolised allergen
Thorax
Early phase bronchoconstriction in the mouse requires allergen-specific IgG
J Immunol
Early and late-phase asthmatic reactions: a hypothesis
Allergy
Early and late-phase bronchoconstriction after allergen challenge of nonanesthetized guinea pigs. I. The association of disordered airway physiology to leukocyte infiltration
Am Rev Respir Dis
Relationship between airway eosinophilia and airway hyperresponsiveness in a late asthmatic model of guinea pigs
Int Arch Allergy Immunol
Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease
Am J Respir Crit Care Med
Early- and late-phase bronchoconstriction, airway hyper-reactivity and cell influx into the lungs, after 5′-adenosine monophosphate inhalation: comparison with ovalbumin
Clin Exp Allergy
Cytokine and eosinophil responses in the lung, peripheral blood and bone marrow compartments in a murine model of allergen-induced airways inflammation
Am J Respir Cell Mol Biol
Murine model of chronic human asthma
Immunol Cell Biol
Mechanisms to tolerance to inhaled allergens: the relevance of a modified Th2 response to allergens from domestic animals
Springer Semin Immunopathol
Cited by (29)
Apolipoprotein E negatively regulates allergic airway inflammation and remodeling in mice with OVA-induced chronic asthma
2023, International Immunopharmacology5-HT<inf>2</inf> receptor activation alleviates airway inflammation and structural remodeling in a chronic mouse asthma model
2019, Life SciencesCitation Excerpt :In an attempt to develop a model of prolonged inflammation and AHR at maximal levels without signs of decrease for two weeks and beyond, we added an additional OVA sensitization on Day 17, and extended weekly nasal OVA exposures to 16 weeks. In our protocol, OVA exposures were performed minimally, once weekly, as opposed to three times per week as is used in some sub-chronic paradigms [32,51], in efforts to reduce allergen chronicity [45] because repeated exposure of antigen to airways can result in tolerance to the allergen [52]. In our chronic OVA exposure model, we are able to generate several key symptoms relevant to asthma.
Progressive increase in allergen concentration abrogates immune tolerance in ovalbumin-induced murine model of chronic asthma
2018, International ImmunopharmacologyDeath Receptor 3 regulates distinct pathological attributes of acute versus chronic murine allergic lung inflammation
2017, Cellular ImmunologyCitation Excerpt :All procedures were approved by the Local Research Ethics Committee and performed in accordance with Home Office approved license PPL 30/2580. As previously described [34], mice were sensitised on days 0 and 5 via an i.p. injection containing 100 µg chicken OVA (VWR) [34] emulsified with 50 mg aluminium hydroxide (Thermo Scientific). To study acute pulmonary inflammation, on day 15 mice were challenged twice, 4 h apart for 1 h via inhalation with a 0.5% (w/v) solution of OVA or PBS.
Adjustment of sensitisation and challenge protocols restores functional and inflammatory responses to ovalbumin in guinea-pigs
2015, Journal of Pharmacological and Toxicological MethodsCitation Excerpt :Guinea-pigs have a similar distribution of mast cells, to humans (Fuchs et al., 2012). Also, the EAR bronchoconstriction is pronounced and mediated by histamine, cysteinyl leukotrienes and prostaglandins in both species, contrasting with mice where the EAR bronchoconstriction is minimal and mediated by 5-HT (Fernandez-Rodriguez, Ford, Broadley, & Kidd, 2008; Moffatt, Cocks, & Page, 2004; Ressmeyer et al., 2006; Zosky et al., 2008). Several groups have demonstrated isolated characteristics of asthma such as AHR, EAR and LAR in guinea-pigs (Riley et al., 2013; Suda et al., 2009).
Key mediators in the immunopathogenesis of allergic asthma
2014, International Immunopharmacology
- 1
Current address: Department of Diagnostic Radiology, Wales Heart Research Institute, Wales College of Medicine, Heath Park, Cardiff, CF14 4XN, UK.